Telavancin

DB06402ApprovedInvestigationalSmall moleculeLipoglycopeptide Antibacterial

Telavancin is an antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia. Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.

Mechanism: Telavancin is a bactericidal lipoglycopeptide that is active against a broad range of gram-positive bacteria. Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to the acyl-D-alanyl-D-alanine (D-Ala-D-Ala) terminus cell wall precursors. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin.
Curator reviewed
Primary indication: For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group.Curator reviewed · 4 structured indications
Formula / weight: C₈₀H₁₀₆Cl₂N₁₁O₂₇P · 1755.65 g/mol (avg)
First approval: Canada, 2014 · United States, 2009
Brand names: Vibativ

Resolves to

Compound

UNIIXK134822Z0CAS372151-71-8ChEMBLCHEMBL507870ChEBI71229PubChem3081362

Clinical / RWD

RxNorm473837ATCJ01XA03

Structure

InChIKeyONUMZHGUFYIKPM-MXNFEBESSA-NSMILES

CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O

Targets

P34998CRHR1P32297CHRNA3Q15822CHRNA2

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,113Drug interactionsStructured to mechanism, not free text

14Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

13Marketed productsAcross 4 countries and 7 labellers

1ATC codeIncluding every combination product, plus 16 drug categories

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telavancin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account